SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) saw unusually-high trading volume on Wednesday . Approximately 308,297 shares were traded during mid-day trading, a decline of 13% from the previous session’s volume of 355,262 shares.The stock last traded at $10.35 and had previously closed at $10.50.

The company has a market cap of $522.05 million and a PE ratio of 19.37. The company has a 50-day moving average of $13.28 and a 200-day moving average of $11.21.

SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter. The business earned $36.50 million during the quarter, compared to analysts’ expectations of $33.60 million. Analysts expect that SciClone Pharmaceuticals Inc. will post $0.33 EPS for the current year.

Several hedge funds and institutional investors recently added to or reduced their stakes in SCLN. Matarin Capital Management LLC bought a new position in SciClone Pharmaceuticals during the fourth quarter valued at approximately $1,600,000. GSA Capital Partners LLP increased its position in SciClone Pharmaceuticals by 20.0% in the fourth quarter. GSA Capital Partners LLP now owns 325,115 shares of the specialty pharmaceutical company’s stock valued at $2,991,000 after buying an additional 54,227 shares during the period. Dimensional Fund Advisors LP increased its position in SciClone Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,559,182 shares of the specialty pharmaceutical company’s stock valued at $23,544,000 after buying an additional 53,987 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. increased its position in SciClone Pharmaceuticals by 32.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 198,570 shares of the specialty pharmaceutical company’s stock valued at $1,827,000 after buying an additional 48,470 shares during the period.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.